LeMaitre (LMAT) Q2 Revenue Jumps 15%
LeMaitre Vascular (NASDAQ:LMAT), a medical device company focused on vascular surgeons, reported its latest quarterly earnings after the bell on August 5, 2025. The company delivered GAAP results ahead of expectations, posting GAAP earnings per share of $0.60, above the anticipated $0.57 (GAAP). Revenue (GAAP) reached $64.2 million for Q2 2025, beating GAAP revenue forecasts of $62.48 million and rising significantly from the prior-year total of $55.8 million (GAAP, Q2 2024). Gross margin (GAAP) improved and growth from top products, with management raising guidance for the year. Overall, the period showed continued strength in core product lines, international markets, and direct sales effectiveness.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
LeMaitre Vascular specializes in medical devices for peripheral vascular disease, a condition that restricts blood flow in arteries and veins outside the heart and brain. Its products cater primarily to vascular surgeons, with a focus on treating diseases in limbs and other peripheral areas. The company operates in a market valued at over $5 billion globally and estimates its direct addressable opportunity at nearly $1 billion, based on its assessment of the annual worldwide market for its products.
Source Fool.com
